The United States spent $5.3 trillion on healthcare in 2024, equivalent to approximately 18% of its GDP. Healthcare expenditure grew 7.2% in a single year, continuing to outpace the broader economy.
The scale is extraordinary. But the more important question for healthcare leaders is not how large the market has become. It is whether additional spending is translating into sustainable value.
According to the Centers for Medicare & Medicaid Services (CMS), hospital spending reached $1.63 trillion, physician and clinical services exceeded $1.1 trillion, and retail prescription drug spending totaled $467 billion. Patients themselves contributed approximately $557 billion through out-of-pocket payments.
Where healthcare dollars go
Selected U.S. healthcare expenditures, 2024 · USD billions
Source: CMS National Health Expenditure Fact Sheet. Bars start at zero and use the same scale. Selected service categories, not the full $5.3T total. Out-of-pocket payments are a financing source and overlap with service spending; they are not an additional service category.
A growing market under structural pressure
Healthcare remains one of the world’s largest economic sectors. Yet its expansion is accompanied by growing financial, operational, and political pressures.
Hospitals face complex cost structures. Payers must balance affordability and access. Pharmaceutical and medical technology companies face increasingly demanding evidence and reimbursement environments. Patients expect better experiences, greater transparency, and improved outcomes.
These pressures are changing the meaning of commercial success. Revenue growth alone is no longer a sufficient measure of competitive strength. Increasingly, organizations must demonstrate how their products, services, and partnerships contribute to measurable improvements in healthcare delivery.
Where the opportunities are emerging
First, productivity and operational transformation. AI-enabled workflows, intelligent automation, and better integration of clinical and administrative processes offer opportunities to improve capacity and efficiency. Their economic value, however, depends on successful implementation and measurable outcomes.
Second, integrated care models. Healthcare organizations can create value by connecting diagnostics, treatment, monitoring, and follow-up rather than optimizing each activity independently. This requires partnerships across traditionally fragmented parts of the healthcare ecosystem.
Third, evidence-driven commercial models. Manufacturers and service providers that can demonstrate clinical relevance, economic benefits, and operational fit will be better positioned to engage healthcare systems and payers.
The Global OneHealth view
The next phase of healthcare competition will reward organizations that understand the entire value chain.
For pharmaceutical companies, that means looking beyond product differentiation toward access, patient pathways, and strategic partnerships. For HealthTech innovators, it means moving beyond technological capabilities toward validated business models. For investors, it means distinguishing market growth from sustainable economic value. And for healthcare systems, it means identifying where innovation can improve both outcomes and resource utilization.
The organizations best positioned for the next decade will not necessarily be those participating in the largest markets. They will be those capable of transforming healthcare expenditure into demonstrable value.
Sources and reference links
Figures and context are drawn from the source above. Strategic interpretation and visuals are Global OneHealth editorial analysis.
The Global OneHealth View — From Insight to Action.
← All articles